“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve,” said
“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization,” said
Third Quarter 2026 Financial Results
Key financial highlights include (dollars in millions, except per share data):
| Three Months Ended |
|
| Percentage Change | ||||||||
| 2026 |
| 2025 |
|
| |||||||
|
|
|
|
|
|
|
| |||||
Total revenues | $ | 832.5 |
| $ | 799.5 |
| $ | 33.0 |
|
| 4 | % |
Net income | $ | 258.6 |
| $ | 338.7 |
| $ | (80.1 | ) |
| (24 | )% |
Net income, per basic share | $ | 6.06 |
| $ | 7.73 |
| $ | (1.67 | ) |
| (22 | )% |
Net income, per diluted share | $ | 5.71 |
| $ | 7.16 |
| $ | (1.45 | ) |
| (20 | )% |
Revenues
The table below presents the components of total revenues (dollars in millions):
| Three Months Ended |
|
| Percentage Change | ||||||||
| 2026 |
| 2025 |
|
| |||||||
Net product sales: |
|
|
|
|
|
|
| |||||
Tyvaso DPI® | $ | 378.5 |
| $ | 336.2 |
| $ | 42.3 |
|
| 13 | % |
Nebulized Tyvaso® |
| 125.3 |
|
| 141.8 |
|
| (16.5 | ) |
| (12 | )% |
Total Tyvaso |
| 503.8 |
|
| 478.0 |
|
| 25.8 |
|
| 5 | % |
Remodulin®(1) |
| 122.0 |
|
| 125.9 |
|
| (3.9 | ) |
| (3 | )% |
Orenitram® |
| 145.0 |
|
| 131.1 |
|
| 13.9 |
|
| 11 | % |
Unituxin® |
| 52.3 |
|
| 47.9 |
|
| 4.4 |
|
| 9 | % |
Adcirca® |
| 4.5 |
|
| 9.7 |
|
| (5.2 | ) |
| (54 | )% |
Other |
| 4.9 |
|
| 6.9 |
|
| (2.0 | ) |
| (29 | )% |
Total revenues | $ | 832.5 |
| $ | 799.5 |
| $ | 33.0 |
|
| 4 | % |
(1) | Net product sales include sales of infusion devices, including the Remunity® and RemunityPRO® Pumps. |
Total Tyvaso revenues increased by five percent to
The table below presents the breakdown of total revenues between
| Three Months Ended | ||||||||||||
| 2026 |
| 2025 | ||||||||||
| ROW | Total |
| ROW | Total | ||||||||
Net product sales: |
|
|
|
|
|
|
| ||||||
Tyvaso DPI | $ | 378.2 | $ | 0.3 | $ | 378.5 |
| $ | 336.2 | $ | — | $ | 336.2 |
Nebulized Tyvaso |
| 118.0 |
| 7.3 |
| 125.3 |
|
| 133.9 |
| 7.9 |
| 141.8 |
Total Tyvaso |
| 496.2 |
| 7.6 |
| 503.8 |
|
| 470.1 |
| 7.9 |
| 478.0 |
Remodulin(1) |
| 108.5 |
| 13.5 |
| 122.0 |
|
| 110.7 |
| 15.2 |
| 125.9 |
Orenitram |
| 145.0 |
| — |
| 145.0 |
|
| 131.1 |
| — |
| 131.1 |
Unituxin |
| 49.9 |
| 2.4 |
| 52.3 |
|
| 46.5 |
| 1.4 |
| 47.9 |
Adcirca |
| 4.5 |
| — |
| 4.5 |
|
| 9.7 |
| — |
| 9.7 |
Other |
| 4.4 |
| 0.5 |
| 4.9 |
|
| 6.7 |
| 0.2 |
| 6.9 |
Total revenues | $ | 808.5 | $ | 24.0 | $ | 832.5 |
| $ | 774.8 | $ | 24.7 | $ | 799.5 |
(1) | Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps. |
Expenses
Cost of sales. The table below summarizes cost of sales by major category (dollars in millions):
| Three Months Ended |
|
| Percentage Change | ||||||||
| 2026 |
| 2025 |
|
| |||||||
Category: |
|
|
|
|
|
|
| |||||
Cost of sales | $ | 98.0 |
| $ | 100.0 |
| $ | (2.0 | ) |
| (2 | )% |
Share-based compensation expense(1) |
| 1.1 |
|
| 0.9 |
|
| 0.2 |
|
| 22 | % |
Total cost of sales | $ | 99.1 |
| $ | 100.9 |
| $ | (1.8 | ) |
| (2 | )% |
(1) | See Share-based compensation expense below. |
Research and development expense. The table below summarizes the nature of research and development expense by major expense category (dollars in millions):
| Three Months Ended |
|
| Percentage Change | |||||||
| 2026 |
| 2025 |
|
| ||||||
Category: |
|
|
|
|
|
|
| ||||
External research and development(1) | $ | 77.1 |
| $ | 63.5 |
| $ | 13.6 |
| 21 | % |
Internal research and development(2) |
| 61.0 |
|
| 50.8 |
|
| 10.2 |
| 20 | % |
Share-based compensation expense(3) |
| 11.1 |
|
| 8.4 |
|
| 2.7 |
| 32 | % |
Other(4) |
| 130.0 |
|
| 4.8 |
|
| 125.2 |
| NM(5) | |
Total research and development expense | $ | 279.2 |
| $ | 127.5 |
| $ | 151.7 |
| 119 | % |
(1) | External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before regulatory approval of the relevant product. | |
(2) | Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before regulatory approval, and internal facilities-related expenses, including depreciation, related to research and development activities. | |
(3) | See Share-based compensation expense below. | |
(4) | Other primarily includes costs to acquire certain in-process research and development (IPR&D) assets, upfront fees and milestone payments to third parties under license agreements related to development-stage products, and adjustments to the fair value of our contingent consideration obligations. | |
(5) | Calculation is not meaningful. |
Research and development, excluding share-based compensation. The increase in research and development expense for the three months ended
Selling, general, and administrative expense. The table below summarizes selling, general, and administrative expense by major category (dollars in millions):
| Three Months Ended |
|
| Percentage Change | |||||||||
| 2026 |
| 2025 |
|
| ||||||||
Category: |
|
|
|
|
|
|
| ||||||
General and administrative(1) | $ | 143.1 |
|
| $ | 123.7 |
| $ | 19.4 |
|
| 16 | % |
Litigation accrual |
| (66.5 | ) |
|
| 0.8 |
|
| (67.3 | ) |
| NM(3) | |
Sales and marketing |
| 41.0 |
|
|
| 28.3 |
|
| 12.7 |
|
| 45 | % |
Share-based compensation expense(2) |
| 28.8 |
|
|
| 29.8 |
|
| (1.0 | ) |
| (3 | )% |
Total selling, general, and administrative expense | $ | 146.4 |
|
| $ | 182.6 |
| $ | (36.2 | ) |
| (20 | )% |
(1) | Excluding litigation accrual. See Litigation accrual section below. | |
(2) | See Share-based compensation expense below. | |
(3) | Calculation is not meaningful. |
General and administrative, excluding litigation accrual and share-based compensation. The increase in general and administrative expense for the three months ended
Litigation accrual. The change in litigation accrual for the three months ended
Sales and marketing, excluding share-based compensation. The increase in sales and marketing expense for the three months ended
Share-based compensation expense. The table below summarizes share-based compensation expense by major category (dollars in millions):
| Three Months Ended |
|
| Percentage Change | ||||||||
| 2026 |
| 2025 |
|
| |||||||
Category: |
|
|
|
|
|
|
| |||||
Stock options | $ | 11.0 |
| $ | 11.3 |
| $ | (0.3 | ) |
| (3 | )% |
Restricted stock units |
| 29.1 |
|
| 27.1 |
|
| 2.0 |
|
| 7 | % |
Employee stock purchase plan |
| 0.9 |
|
| 0.7 |
|
| 0.2 |
|
| 29 | % |
Total share-based compensation expense | $ | 41.0 |
| $ | 39.1 |
| $ | 1.9 |
|
| 5 | % |
Interest income. Interest income was
Other income, net. Other income, net was
Income tax expense. Income tax expense for the three months ended
Share repurchases. In
During the three months ended
During the three months ended
In
Webcast
We will host a webcast to discuss our third quarter 2026 financial results on
About United Therapeutics
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements related to: our future growth and growth outlook; our portfolio of therapies and their potential to exponentially increase the number of patients that we can serve; new opportunities across cardiopulmonary and respiratory medicine; the timing of the final settlement of the September 2026 ASR; the timing, structure and use of our share repurchase program; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of November 4, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.
ORENITRAM, REMODULIN, REMUNITY, REMUNITYPRO, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation.
ADCIRCA is a registered trademark of Eli Lilly and Company.
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
(In millions, except per share data) | |||||||
| Three Months Ended | ||||||
|
| 2026 |
|
|
| 2025 |
|
| (Unaudited) | ||||||
Total revenues | $ | 832.5 |
|
| $ | 799.5 |
|
Operating expenses: |
|
|
| ||||
Cost of sales |
| 99.1 |
|
|
| 100.9 |
|
Research and development |
| 279.2 |
|
|
| 127.5 |
|
Selling, general, and administrative |
| 146.4 |
|
|
| 182.6 |
|
Total operating expenses |
| 524.7 |
|
|
| 411.0 |
|
Operating income |
| 307.8 |
|
|
| 388.5 |
|
Interest income |
| 33.7 |
|
|
| 46.4 |
|
Interest expense |
| (2.9 | ) |
|
| (3.0 | ) |
Other income, net |
| 34.2 |
|
|
| 6.1 |
|
Total other income, net |
| 65.0 |
|
|
| 49.5 |
|
Income before income taxes |
| 372.8 |
|
|
| 438.0 |
|
Income tax expense |
| (114.2 | ) |
|
| (99.3 | ) |
Net income | $ | 258.6 |
|
| $ | 338.7 |
|
Net income per common share: |
|
|
| ||||
Basic | $ | 6.06 |
|
| $ | 7.73 |
|
Diluted | $ | 5.71 |
|
| $ | 7.16 |
|
Weighted average number of common shares outstanding: |
|
|
| ||||
Basic |
| 42.7 |
|
|
| 43.8 |
|
Diluted |
| 45.3 |
|
|
| 47.3 |
|
SELECTED CONSOLIDATED BALANCE SHEET DATA | ||
(Unaudited, in millions) | ||
|
| |
Cash, cash equivalents, and marketable investments | $ | 3,535.7 |
Total assets |
| 7,034.1 |
Total liabilities |
| 758.1 |
Total stockholders’ equity |
| 6,276.0 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104979180/en/
For Further Information Contact:
Investor Inquiries
https://ir.unither.com/contact-ir
Media Inquiries
communications@unither.com
Source: